Following intravenous injection of FC‐PSMA for 48 h, the TNR tumor/leg ratio reached 12.16 ± 0.90, providing high‐performance NIR‐II fluorescence imaging guidance for prostate cancer resection surgery. The gene discussed is FOLH1; the disease is prostate cancer.